Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lück

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinumA du Bois, H J Lück, K Buser, et al.
Seminars in Oncology|December 1, 1995
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancerH G Meerpohl, A du Bois, H Kühnle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2012
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patientsE-F Solomayer, G Gebauer, P Hirnle, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
Gynecologic Oncology|July 8, 2011
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study GroupK Baumann, J Pfisterer, P Wimberger, et al.
Seminars in Oncology|February 1, 1997
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 8, 2001
The integration of anthracyclines in the treatment of advanced ovarian cancerH J Lück, A Du Bois, B Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapyP Reichardt, G Von Minckwitz, P C Thuss-Patience, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinumA du Bois, H J Lück, K Buser, et al.
Seminars in Oncology|December 1, 1995
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancerH G Meerpohl, A du Bois, H Kühnle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2012
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patientsE-F Solomayer, G Gebauer, P Hirnle, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
Gynecologic Oncology|July 8, 2011
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study GroupK Baumann, J Pfisterer, P Wimberger, et al.
Seminars in Oncology|February 1, 1997
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 8, 2001
The integration of anthracyclines in the treatment of advanced ovarian cancerH J Lück, A Du Bois, B Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapyP Reichardt, G Von Minckwitz, P C Thuss-Patience, et al.
Pageof 5